CN113795251B - 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途 - Google Patents

酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途

Info

Publication number
CN113795251B
CN113795251B CN202080031455.3A CN202080031455A CN113795251B CN 113795251 B CN113795251 B CN 113795251B CN 202080031455 A CN202080031455 A CN 202080031455A CN 113795251 B CN113795251 B CN 113795251B
Authority
CN
China
Prior art keywords
compounds
clpp
alkyl
optionally substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080031455.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113795251A (zh
Inventor
E·伊瓦诺维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madeira Therapy
Original Assignee
Madeira Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madeira Therapy filed Critical Madeira Therapy
Priority to CN202511975073.7A priority Critical patent/CN121758447A/zh
Publication of CN113795251A publication Critical patent/CN113795251A/zh
Application granted granted Critical
Publication of CN113795251B publication Critical patent/CN113795251B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080031455.3A 2019-02-27 2020-02-26 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途 Active CN113795251B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511975073.7A CN121758447A (zh) 2019-02-27 2020-02-26 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962811432P 2019-02-27 2019-02-27
US62/811,432 2019-02-27
US201962819204P 2019-03-15 2019-03-15
US62/819,204 2019-03-15
US201962825667P 2019-03-28 2019-03-28
US62/825,667 2019-03-28
US201962840254P 2019-04-29 2019-04-29
US62/840,254 2019-04-29
US201962871694P 2019-07-08 2019-07-08
US62/871,694 2019-07-08
US201962885055P 2019-08-09 2019-08-09
US62/885,055 2019-08-09
US201962901142P 2019-09-16 2019-09-16
US62/901,142 2019-09-16
US201962931043P 2019-11-05 2019-11-05
US62/931,043 2019-11-05
US202062975088P 2020-02-11 2020-02-11
US62/975,088 2020-02-11
PCT/US2020/019944 WO2020176654A1 (en) 2019-02-27 2020-02-26 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511975073.7A Division CN121758447A (zh) 2019-02-27 2020-02-26 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途

Publications (2)

Publication Number Publication Date
CN113795251A CN113795251A (zh) 2021-12-14
CN113795251B true CN113795251B (zh) 2026-01-13

Family

ID=72238693

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080031455.3A Active CN113795251B (zh) 2019-02-27 2020-02-26 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途
CN202511975073.7A Pending CN121758447A (zh) 2019-02-27 2020-02-26 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511975073.7A Pending CN121758447A (zh) 2019-02-27 2020-02-26 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途

Country Status (7)

Country Link
US (1) US12459945B2 (https=)
EP (1) EP3930714A4 (https=)
JP (1) JP7709379B2 (https=)
CN (2) CN113795251B (https=)
AU (2) AU2020228047B2 (https=)
CA (1) CA3131740A1 (https=)
WO (1) WO2020176654A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
EP4337214A4 (en) * 2021-05-13 2025-01-29 Chimerix, Inc. USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMAS
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
WO2024030645A1 (en) * 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
WO2024199457A1 (zh) * 2023-03-31 2024-10-03 苏州安赛隆医药科技有限公司 并环结构化合物、其制备方法及其用途以及药物组合物及其用途
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
EP4488279A1 (en) * 2023-07-03 2025-01-08 Centro Atlantico del Medicamento S.A (Ceamed, S.A) Substituted hexahydro-2h-pyrazino[1,2-a]pyrazin-1(6h)-one derivatives as activators of human caseinolytic protease p (hsclpp)
WO2025011546A1 (en) * 2023-07-10 2025-01-16 Acelon Therapeutics Human caseinolytic protease p agonists and uses thereof
CN119306718A (zh) * 2023-07-11 2025-01-14 中科中山药物创新研究院 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754961A (zh) * 2007-04-20 2010-06-23 先灵公司 嘧啶酮衍生物及其使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
DE59408453D1 (de) 1993-04-23 1999-08-12 Hoechst Ag Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
US20110275647A1 (en) * 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
WO2012079164A1 (en) 2010-12-16 2012-06-21 The Governing Council Of The University Of Toronto Activators of cylindrical proteases
LT3662910T (lt) 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
AU2017310529B2 (en) 2016-08-12 2021-08-19 Edwin J. Iwanowicz Protein kinase regulators
WO2018031987A1 (en) 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
US20220143024A1 (en) 2019-02-22 2022-05-12 Board Of Regents, The University Of Texas System Methods of using imipridones
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754961A (zh) * 2007-04-20 2010-06-23 先灵公司 嘧啶酮衍生物及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAS No：2121092-58-6;REGISTRY;STN;20170828;1 *
CAS No：2121092-64-4;REGISTRY;STN;20170828;1 *

Also Published As

Publication number Publication date
CN121758447A (zh) 2026-03-31
EP3930714A4 (en) 2022-10-26
WO2020176654A1 (en) 2020-09-03
AU2026201069A1 (en) 2026-03-12
US12459945B2 (en) 2025-11-04
JP7709379B2 (ja) 2025-07-16
AU2020228047B2 (en) 2025-11-20
US20220089596A1 (en) 2022-03-24
JP2022521797A (ja) 2022-04-12
WO2020176654A8 (en) 2020-10-08
EP3930714A1 (en) 2022-01-05
AU2020228047A1 (en) 2021-09-30
CA3131740A1 (en) 2020-09-03
CN113795251A (zh) 2021-12-14

Similar Documents

Publication Publication Date Title
CN113795251B (zh) 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途
US11919904B2 (en) Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) Tricyclic amine compounds as CDK2 inhibitors
KR101813830B1 (ko) 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
EP3154959B1 (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
JP5956653B2 (ja) １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
CN108883112B (zh) 用于癌症患者分级和癌症治疗的化合物、组合物和方法
JP2021020957A (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
AU2021372427A1 (en) Compounds for targeted protein degradation of kinases
US20200181154A1 (en) Pyrazole carboxamide compounds and methods of use
WO2022261257A1 (en) Stapled peptides and methods thereof
KR20180134860A (ko) 암의 치료를 위한 taf1 억제제
EP3496724B1 (en) Protein kinase regulators
CA3194868A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
US20230339947A1 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
CA3174972A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
EP4612154A1 (en) Regulators of porphyrin and intermediates
CN117794560A (zh) 订书钉化肽及其方法
WO2025151850A9 (en) Spirocycle acrylamides that stereo- and site-selectively degrade the transcriptional and dna-damage response protein ercc3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant